Theseus Pharmaceuticals Investor Relations Material

Theseus Pharmaceuticals Inc., trading under the NASDAQ symbol THRX, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for cancer patients. The company's leading product candidate is THE-630, a pan-KIT inhibitor aimed at treating gastrointestinal stromal tumors. Additionally, Theseus is developing THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor intended for use in non-small cell lung cancer patients who have developed resistance to first- or later-line osimertinib treatment. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.